Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 8 December 2025 - 18 December 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a whiplash week for the stock, a surge in attention, and a new set of near-term catalysts that now matter more…
18 December 2025
····
Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune, Inc. (NASDAQ: ALT) is back in the biotech spotlight on December 17, 2025—less because the company suddenly became “safe,” and more because it’s heading into the kind of binary stretch that turns small-cap biotech charts into roller coasters: a high-stakes clinical update is expected before year-end, leadership is changing hands, and Wall Street price targets remain dramatically spread out.…
17 December 2025
·····
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

December 15, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX) is back on investors’ radar today as fresh coverage and new analysis dig into a major European regulatory milestone for its lead therapy ANKTIVA (nogapendekin alfa inbakicept). The market’s obsession is simple: does this become the catalyst that turns ImmunityBio into a real commercial oncology story—or just the latest biotech pop before…
15 December 2025
····
CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited shares finished Friday’s session firmly higher, with the biotech giant benefiting from a broader rebound in Australian healthcare stocks and fresh attention on two CSL-specific threads: its ongoing on-market share buyback and the latest long-term durability data for its hemophilia B gene therapy, HEMGENIX. Market Index Below is what happened after the bell on 12.12.2025, what the latest…
13 December 2025
···
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for its GLP‑1 franchise. As of Thursday’s close, Eli Lilly shares were trading around $1,006, up roughly 1–1.5% on the day,…
11 December 2025
·····
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics, Inc. (NASDAQ: VERA) is back center stage on December 11, 2025, as traders digest a fresh equity offering, strong late‑stage clinical data, and a newly filed Biologics License Application (BLA) for its lead drug, atacicept, in IgA nephropathy (IgAN). During Thursday’s session, VERA shares were trading around $46, up roughly 3–4% on the day and near 52‑week highs,…
11 December 2025
·····
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. (NASDAQ: BLTE) has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range. BioPharma Dive As of…
11 December 2025
·····
Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. (NASDAQ: DYN) shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In early afternoon U.S. trading, Dyne stock was changing hands around $19.15, down roughly 14% on the day after opening near…
9 December 2025
·····
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc. As of intraday…
9 December 2025
····
Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Snapshot: Where Structure Therapeutics Stock Stands Today Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly moved from niche obesity biotech to front‑page market story. As of December 9, 2025, GPCR is trading around $69.98, up roughly 102% in a single session compared with its previous close near $34.56. The stock’s intraday range on December 8 ran from $44.74 to $94.90, marking…
9 December 2025
····
Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. (NASDAQ: LEGN) shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow.…
8 December 2025
·····
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. (NASDAQ: KYMR) delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high above $100, on volume far above normal. MarketBeat The catalyst: very strong Phase 1b data for KT‑621, a once‑daily oral…
8 December 2025
···
1 … 6 7 8 9 10 … 12

Stock Market Today

  • Corn Futures Edge Higher Amid Export Sales and Ethanol Production Data
    February 5, 2026, 11:00 AM EST. Corn futures held slight gains midday, with cash corn prices up 1.25 cents to $3.95 1/2. A private export sale of 130,480 metric tons (MT) was reported to unknown destinations, while a South Korean importer bought 65,000 MT in a private tender. Ethanol production fell by 158,000 barrels per day (bpd) to 956,000 bpd last week, with stocks down 264,000 barrels. Exports rose 59,000 bpd. Traders anticipate USDA weekly sales data on Thursday, expecting 0.8-2.1 million MT sold for the week ending Jan. 29. March corn futures stood at $4.29 1/2, up 1 cent, with May and July 2026 contracts also posting modest gains. These moves reflect cautious optimism amid fluctuating demand and production shifts in related markets.
Go toTop